Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Phamatech's QuickScreen Is First At-Home Urine Drug Test Available In U.S.

This article was originally published in The Tan Sheet

Executive Summary

Phamatech plans to begin U.S. sales of the first over-the-counter, at-home urine test for drugs of abuse, between Nov. 20 and Dec. 1. The company's 510(k) application for QuickScreen cleared FDA Oct. 16.

You may also be interested in...



First Check Is First OTC Test To Screen Both Rx And Illicit Drug Use

First Check Diagnostics' First Check 12 Drug Test is the first FDA-approved, over-the-counter drug test that identifies exposure to prescription drugs as well as illicit substances such as marijuana, the firm states

First Check Is First OTC Test To Screen Both Rx And Illicit Drug Use

First Check Diagnostics' First Check 12 Drug Test is the first FDA-approved, over-the-counter drug test that identifies exposure to prescription drugs as well as illicit substances such as marijuana, the firm states

First Check Is First OTC Test To Screen Both Rx And Illicit Drug Use

First Check Diagnostics' First Check 12 Drug Test is the first FDA-approved, over-the-counter drug test that identifies exposure to prescription drugs as well as illicit substances such as marijuana, the firm states

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088983

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel